A neuropatic pain drug from Convergence Pharmaceuticals was "well tolerated" in all participants in a Phase I study, according to a company release.
Few adverse effects were reported for the orally administered drug CNV2197944 in both young and elderly patients, indicating that the drug has an "optimal profile for a chronic pain medication," the company said.
Convergence is currently developing a Phase II trial for the drug.
University of New England Researcher Receives $140K Grant to Study Cancer Pain
Memorial Hospital of Union County, Pain Management Group Open Pain Center
Few adverse effects were reported for the orally administered drug CNV2197944 in both young and elderly patients, indicating that the drug has an "optimal profile for a chronic pain medication," the company said.
Convergence is currently developing a Phase II trial for the drug.
Related Articles on Pain Management:
RS Medical to Launch Nimbus Radiofrequency Ablation DeviceUniversity of New England Researcher Receives $140K Grant to Study Cancer Pain
Memorial Hospital of Union County, Pain Management Group Open Pain Center